profit from every $100 of sales.
$0$100
Scilex
$0.04+43.01% today
-72.1% in 1 year
1-year low $0.031-year high $0.30
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Scilex vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Scilex | No profit yet | ||
 Eli Lilly | 62.3× · Very expensive | ||
 Johnson & Johnson | 25.7× · Fair price | ||
 AbbVie | 123.4× · Very expensive | ||
 Roche | 25.5× · Fair price |
AI analysis
An AI analyst reads Scilex's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- 0.00
- -0.4×
- 2.2×
- 19.4×
- –
- 241.0%
- -466.5%
- 0.0%
Profitability
- 59.7%
- -900.4%
- -1,330.4%
- -1,166.2%
- 1,032.0%
- 169.4%
- 190.5%
- -110.3%
- 229.5%
- 68.5%
Growth
- −0.9%
- –
- −81.0%
- –
- +30.6%
Financial health
- -0.4×
- -0.64
- 36.3%
- -23.8×
- 0.08
- 0.07
- 0.08
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 16%of 908
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Feb 25, 2026 | -0.47 | -0.47 | +0.0% |
| Nov 14, 2025 | -22.17 | -22.17 | +0.0% |
| Aug 13, 2025 | -3.65 | -0.91 | −301.0% |
| Apr 29, 2025 | -0.04 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/5Passes 2 of 5. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
48No pass
Benjamin Graham
4No pass
Philip Fisher
55No pass
Peter Lynch
–Not enough data
Joel Greenblatt
–Not enough data
Charlie Munger
72Pass
Terry Smith
63Pass
Questions about Scilex
Is Scilex a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 5 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Scilex AI analysis
What does Scilex do?
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. It is in Drug Manufacturers - General.
Does Scilex pay a dividend?
No. Scilex does not pay a dividend at the moment.
How has Scilex stock done over the past year?
Down 72.1% over the past twelve months, to $0.04. It traded between $0.03 and $0.30 and is 86.9% below its high.
Who are Scilex's competitors?
The largest listed companies in the same industry are Eli Lilly, Johnson & Johnson, AbbVie and Roche. The peers table on this page compares their profit, growth and price with Scilex's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.